In conclusion, the significant changes in the plasma profile of all biologically active substances evaluated in our study, which are secreted by the adipose tissue, i.e., omentin-1, NGAL, and CTRP3, suggest their potential diagnostic utility in monitoring metabolic changes associated with the introduction of insulin treatment in type 2 diabetic patients. This evidence concerns the gene LCN2 and type 2 diabetes mellitus.